Perspective in optimization of stem cell therapies for heart regeneration.

IF 0.3
Paulina Gapska, Maciej Kurpisz
{"title":"Perspective in optimization of stem cell therapies for heart regeneration.","authors":"Paulina Gapska,&nbsp;Maciej Kurpisz","doi":"10.5604/01.3001.0010.6665","DOIUrl":null,"url":null,"abstract":"<p><p>There is a variety of mechanisms(s) factor(s) that may influence stem cell therapies for heart regeneration. Among the best candidates for stem cell source are: mesenchymal stem cells (also those isolated from adipose tissue), cardiac cell progenitors (CPC) and descendants of iPSC cells. iPSC/s can be potentially beneficial although their pluripotent induction has been still in question due to: low propagation efficacy, danger of genomic integration/instability, biological risk of current vector system teratoma formation etc. which have been discussed in this review. Optimization protocols are required in order to enhance stem cells resistance to pathological conditions that they may encounter in pathological organ and to increase their retention. Combination between gene transfer and stem cell therapy is now more often used in pre-clinical studies with the prospect of subsequent clinical trials. Complementary substances have been contemplated to support stem cell viability (mainly anti-inflammatory and anti- apoptotic agents), which have been tested in animal models with promising results. Integration of nanotechnology both for efficient stem cell imaging as well as with the aim to provide cell supporting scaffolds seem to be inevitable for further development of cellular therapies. The whole organ (heart) reconstruction as well as biodegradable scaffolds and scaffold-free cell sheets have been also outlined.</p>","PeriodicalId":87132,"journal":{"name":"Postepy higieny i medycyny doswiadczalnej (Online)","volume":"71 0","pages":"975-987"},"PeriodicalIF":0.3000,"publicationDate":"2017-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy higieny i medycyny doswiadczalnej (Online)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5604/01.3001.0010.6665","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

There is a variety of mechanisms(s) factor(s) that may influence stem cell therapies for heart regeneration. Among the best candidates for stem cell source are: mesenchymal stem cells (also those isolated from adipose tissue), cardiac cell progenitors (CPC) and descendants of iPSC cells. iPSC/s can be potentially beneficial although their pluripotent induction has been still in question due to: low propagation efficacy, danger of genomic integration/instability, biological risk of current vector system teratoma formation etc. which have been discussed in this review. Optimization protocols are required in order to enhance stem cells resistance to pathological conditions that they may encounter in pathological organ and to increase their retention. Combination between gene transfer and stem cell therapy is now more often used in pre-clinical studies with the prospect of subsequent clinical trials. Complementary substances have been contemplated to support stem cell viability (mainly anti-inflammatory and anti- apoptotic agents), which have been tested in animal models with promising results. Integration of nanotechnology both for efficient stem cell imaging as well as with the aim to provide cell supporting scaffolds seem to be inevitable for further development of cellular therapies. The whole organ (heart) reconstruction as well as biodegradable scaffolds and scaffold-free cell sheets have been also outlined.

心脏再生干细胞治疗的优化前景。
有多种机制(s)因素可能影响干细胞治疗心脏再生。干细胞来源的最佳候选细胞包括:间充质干细胞(也包括从脂肪组织中分离的干细胞)、心脏细胞祖细胞(CPC)和iPSC细胞的后代。iPSC/s可能是有益的,尽管其多能诱导仍然存在问题,因为:繁殖效率低,基因组整合/不稳定的危险,当前载体系统畸胎瘤形成的生物学风险等,这些在本文中已经讨论过。为了增强干细胞在病理器官中可能遇到的病理条件的抵抗力并增加其保留,需要优化方案。基因转移和干细胞治疗的结合现在更常用于临床前研究,并有后续临床试验的前景。补充物质(主要是抗炎剂和抗凋亡剂)已被考虑支持干细胞的活力,这些物质已在动物模型中进行了测试,结果很有希望。纳米技术在干细胞成像和提供细胞支持支架方面的整合对于细胞治疗的进一步发展是不可避免的。整个器官(心脏)重建以及可生物降解支架和无支架细胞片也已概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信